Researchers at Albert Einstein College of Medicine reported a modular protein scaffold (HCW9206) that links IL‑7, IL‑15 and IL‑21 to generate CAR‑T cells enriched in T memory stem cells, substantially prolonging persistence and disease control in mouse models of hematologic cancer and HIV. The approach produced cell populations with higher self‑renewal capacity than standard activation protocols, according to a Science Advances paper. The multi‑cytokine platform aims to address a key limitation in adoptive cell therapy—loss of persistence and relapse. Authors note the strategy’s manufacturing implications and the need for clinical testing to confirm safety, durability and translation to human dosing regimens.